Detalhe da pesquisa
1.
Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.
BMC Cancer
; 23(1): 66, 2023 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36658529
2.
Physician- and patient-reported symptom concordance and association with quality of life in hepatocellular carcinoma.
Future Oncol
; 18(33): 3727-3740, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377818
3.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Lancet Oncol
; 22(10): 1468-1482, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592180
4.
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities.
Clin Lymphoma Myeloma Leuk
; 24(2): e1-e12, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923653
5.
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative.
Clin Pharmacol Ther
; 108(4): 817-825, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32301116
6.
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
ESMO Open
; 5(4)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817068
7.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Clin Cancer Res
; 25(23): 6976-6985, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31481511
8.
AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
Mol Cancer Ther
; 5(7): 1790-9, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16891465
9.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Eur J Cancer
; 81: 17-25, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28591675
10.
Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
Lung Cancer
; 92: 35-40, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26775594
11.
Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.
Drugs Context
; 42015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25834620
12.
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Lung Cancer
; 90(3): 427-32, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26791802
13.
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Lung Cancer
; 88(2): 215-22, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25748103
14.
Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.
Clin Lung Cancer
; 14(6): 726-35, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23910068
15.
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
Eur J Cancer
; 100: 135-136, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29970352
16.
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Lung Cancer
; 78(3): 263-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23040326
17.
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 10(4): 252-6, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19632943
18.
AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin.
Cancer Res
; 67(21): 10491-500, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17974993